Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1031 to 1040 of 2733 total matches.

A New Botulinum Toxin (Xeomin) for Cervical Dystonia and Blepharospasm

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2010  (Issue 1351)
for treatment of cervical dystonia. Botox is also approved for treatment of blepharospasm. 1 CERVICAL ...
The FDA has approved incobotulinumtoxinA (Xeomin – Merz) for treatment of cervical dystonia and blepharospasm in adults. It has been commercially available in Germany since 2005. Several formulations of botulinum toxin type A (Botox; Dysport) and type B (Myobloc) are already marketed for treatment of cervical dystonia. Botox is also approved for treatment of blepharospasm.
Med Lett Drugs Ther. 2010 Nov 15;52(1351):90-1 |  Show IntroductionHide Introduction

Mifepristone (Korlym) for Cushing's Syndrome

   
The Medical Letter on Drugs and Therapeutics • Jun 11, 2012  (Issue 1392)
to glucocorticoid receptors and, to a lesser extent, androgen receptors. Table 1. Pharmacology Formulation 300-mg ...
The FDA has approved the antiprogestin mifepristone (Korlym – Corcept Therapeutics) for control of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing’s syndrome who have type 2 diabetes/ glucose intolerance and have not responded to, or are not candidates for, surgery. Formerly known as RU 486, mifepristone is also available in a lower strength as Mifeprex for use in terminating an early intrauterine pregnancy.
Med Lett Drugs Ther. 2012 Jun 11;54(1392):46-7 |  Show IntroductionHide Introduction

A New Scorpion Antivenom

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012  (Issue 1393)
17,000 scorpion stings are reported every year in the US.1 Arizona alone reports more than 10,000 ...
Anascorp (Rare Disease Therapeutics), an intravenously administered antivenom derived from horse serum, has been approved by the FDA for treatment of clinical signs of scorpion envenomation.
Med Lett Drugs Ther. 2012 Jun 25;54(1393):51-2 |  Show IntroductionHide Introduction

Renal Sympathetic Denervation for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012  (Issue 1394)
Publication CLINICAL STUDIES — The first study of the cathether-based procedure (Symplicity HTN-1) included ...
Renal sympathetic denervation is under investigation as a therapeutic option for hypertension that has not responded to ≥3 antihypertensive drugs (resistant hypertension).
Med Lett Drugs Ther. 2012 Jul 9;54(1394):55 |  Show IntroductionHide Introduction

Pimavanserin (Nuplazid) for Parkinson's Disease Psychosis

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016  (Issue 1496)
% of patients with Parkinson’s disease.1 Low doses of clozapine (Clozaril, and others) have been effective ...
The FDA has approved the atypical antipsychotic pimavanserin (Nuplazid – Acadia) for treatment of hallucinations and delusions associated with Parkinson's disease. It is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2016 Jun 6;58(1496):74-5 |  Show IntroductionHide Introduction

Dapagliflozin (Farxiga) - A New Indication for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020  (Issue 1601)
diabetes and established cardiovascular disease (CVD) or multiple cardiovascular risk factors,1,2 has now ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga), which was initially approved by the FDA for treatment of type 2 diabetes and then to reduce the risk of hospitalization for HF in adults who have type 2 diabetes and established cardiovascular disease (CVD) or multiple cardiovascular risk factors, has now been approved for a third indication: to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in patients with heart failure with reduced ejection fraction (with or without type 2 diabetes). It is the first SGLT2 inhibitor to...
Med Lett Drugs Ther. 2020 Jun 29;62(1601):102-3 |  Show IntroductionHide Introduction

In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021  (Issue 1638)
years old.1 The original formulation of Comirnaty (30 mcg/0.3 mL) is FDA-licensed for use in persons ...
The FDA has issued an Emergency Use Authorization (EUA) for a lower-strength (10 mcg/0.2 mL) formulation of the mRNA-based COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) for use in children 5-11 years old. The original formulation of (Comirnaty) (30 mcg/0.3 mL) is FDA-licensed for use in persons ≥16 years old and available under an EUA for use in adolescents 12-15 years old.
Med Lett Drugs Ther. 2021 Nov 29;63(1638):185 |  Show IntroductionHide Introduction

Hemgenix - A Gene Therapy for Hemophilia B

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
annualized bleeding rate (ABR) 7-18 months post-infusion was 1.9, compared to 4.1 during the 6-month lead ...
Etranacogene dezaparvovec-drlb (Hemgenix – CSL Behring), an adeno-associated virus vector-based gene therapy, has been approved by the FDA for treatment of hemophilia B in adults who currently receive factor IX prophylaxis therapy or have had life-threatening or repeated, serious, spontaneous bleeding episodes. It is the first gene therapy to be approved in the US for this indication.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):9-10   doi:10.58347/tml.2023.1668a |  Show IntroductionHide Introduction

Talazoparib (Talzenna) for Prostate Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023  (Issue 1682)
in another HR gene. Table 1. Pharmacology Class Poly(ADP-ribose) polymerase (PARP) inhibitor Formulation ...
The oral poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib (Talzenna – Pfizer) has been approved by the FDA for use in combination with the androgen receptor blocker enzalutamide (Xtandi) for treatment of adults with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The drug has been available since 2018 for treatment of deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e134-5   doi:10.58347/tml.2023.1682e |  Show IntroductionHide Introduction

Cholesterol Rethink for High-Risk Patients

   
The Medical Letter on Drugs and Therapeutics • May 10, 2004  (Issue 1182)
% in the atorvastatintreated patients, who now had a median LDL cholesterol of 62 mg/dL (1.60 mmol/L), a relative risk ...
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been considered optimal.
Med Lett Drugs Ther. 2004 May 10;46(1182):37-9 |  Show IntroductionHide Introduction